001     300131
005     20250623114858.0
024 7 _ |a 10.1002/ijc.35401
|2 doi
024 7 _ |a pmid:40098437
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
024 7 _ |a altmetric:175266292
|2 altmetric
037 _ _ |a DKFZ-2025-00628
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Aglago, Elom K
|0 0000-0002-0442-3284
|b 0
245 _ _ |a Alcohol and smoking habits in association with hepatocellular carcinoma risk.
260 _ _ |a Bognor Regis
|c 2025
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1750672092_14034
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Aug 15;157(4):644-657
520 _ _ |a We assessed hepatocellular carcinoma (HCC) risk associated with smoking and alcohol consumption and their interactions, using both questionnaire data and objective serum biomarkers. Information on smoking and alcohol consumption was collected at baseline from 450,112 participants of the EPIC cohort, among whom 255 developed HCC after a median follow-up of 14 years. In a nested case-control subset of 108 HCC cases and 108 matched controls, known biomarkers of smoking (cotinine, nicotine) and habitual alcohol consumption (2-hydroxy-3-methylbutyric acid) were annotated from untargeted metabolomics features. Multivariable-adjusted hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were computed, and multiplicative and additive interaction parameters were calculated. Compared to never smokers, current smokers had a higher HCC risk (HR = 2.46, 95% CI = 1.77-3.43) dose-dependently with the number of cigarettes smoked per day (Ptrend <.001). Compared to light drinkers, HCC risk was higher in former (HR = 3.20, 95% CI = 1.70-6.03), periodically heavy (HR = 1.98, 95% CI = 1.11-3.54), and always heavy (HR = 5.51, 95% CI = 2.39-12.7) drinkers. Higher HCC risk was also observed in the highest versus the lowest tertiles of cotinine (OR = 4.88, 95% CI = 1.52-15.70), nicotine (OR = 5.80, 95% CI = 1.33-25.30) and 2-hydroxy-3-methylbutyric acid (OR = 5.89, 95% CI = 1.33-26.12). Questionnaire-assessed smoking and alcohol exposures did not demonstrate an HCC risk interaction at the multiplicative (MI = 0.88, 95% CI = 0.40-1.96) or additive (RERI = 0.71, 95% CI = -10.1 to 23.6; attributable proportion = 0.17, 95% CI = -0.52 to 1.16; synergy index = 1.27, 95% CI = 0.98-1.66) scales. Similar analyses with cotinine, nicotine, and 2-hydroxy-3-methylbutyric acid also did not show interactions between smoking and alcohol consumption on HCC risk. Smoking and alcohol consumption are strong independent risk factors for HCC and do not appear to synergistically impact its risk, but larger studies are needed.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a biological markers
|2 Other
650 _ 7 |a ethanol
|2 Other
650 _ 7 |a interaction
|2 Other
650 _ 7 |a liver cancer
|2 Other
650 _ 7 |a tobacco
|2 Other
700 1 _ |a Ramos, Ines
|b 1
700 1 _ |a Keski-Rahkonen, Pekka
|0 0000-0001-9437-3040
|b 2
700 1 _ |a Chatziioannou, Chrysovalantou
|b 3
700 1 _ |a Freisling, Heinz
|b 4
700 1 _ |a Fedirko, Veronika
|0 0000-0002-7805-9913
|b 5
700 1 _ |a Gunter, Marc J
|b 6
700 1 _ |a Dahm, Christina C
|b 7
700 1 _ |a Langmann, Fie
|b 8
700 1 _ |a Bondonno, Nicola
|b 9
700 1 _ |a Tjønneland, Anne
|b 10
700 1 _ |a Severi, Gianluca
|0 0000-0001-7157-419X
|b 11
700 1 _ |a Truong, Therese
|0 0000-0002-2943-6786
|b 12
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 13
|u dkfz
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 14
|u dkfz
700 1 _ |a Bergmann, Manuela
|b 15
700 1 _ |a Schulze, Matthias B
|b 16
700 1 _ |a Masala, Giovanna
|0 0000-0002-5758-9069
|b 17
700 1 _ |a Pala, Valeria
|0 0000-0001-5438-970X
|b 18
700 1 _ |a de Magistris, Maria Santucci
|b 19
700 1 _ |a Di Girolamo, Chiara
|0 0000-0002-6031-1009
|b 20
700 1 _ |a Lukic, Marko
|0 0000-0002-3608-9743
|b 21
700 1 _ |a Gram, Inger Torhild
|0 0000-0002-0031-4152
|b 22
700 1 _ |a Bonet, Catalina
|b 23
700 1 _ |a Sánchez, Maria-Jose
|b 24
700 1 _ |a Chirlaque, María-Dolores
|b 25
700 1 _ |a Amiano, Pilar
|b 26
700 1 _ |a Guevara, Marcela
|b 27
700 1 _ |a Vermeulen, Roel
|b 28
700 1 _ |a Manjer, Jonas
|0 0000-0002-3158-5289
|b 29
700 1 _ |a Eriksson, Linda
|b 30
700 1 _ |a Key, Tim J
|b 31
700 1 _ |a Mayen, Ana-Lucia
|b 32
700 1 _ |a Dossus, Laure
|b 33
700 1 _ |a Weiderpass, Elisabete
|b 34
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 35
700 1 _ |a Ferrari, Pietro
|b 36
700 1 _ |a Jenab, Mazda
|0 0000-0002-0573-1852
|b 37
773 _ _ |a 10.1002/ijc.35401
|g p. ijc.35401
|0 PERI:(DE-600)1474822-8
|n 4
|p 644-657
|t International journal of cancer
|v 157
|y 2025
|x 0020-7136
909 C O |p VDB
|o oai:inrepo02.dkfz.de:300131
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2022
|d 2024-12-17
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2022
|d 2024-12-17
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21